A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis
Latest Information Update: 03 May 2019
At a glance
- Drugs Parimifasor (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Lycera
- 02 May 2019 This trial was discontinued in Netherlands (end date: 2018-06-29), according to European Clinical Trials Database.
- 05 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 03 Mar 2019 This trial was completed in Czech Republic (end date: 2018-06-29), according to European Clinical Trials Database.